Investigating the effect of oncolytic vaccinia virus: in vitro and mouse model of non-small cell lung carcinoma

NSCLC-type lung cancers are highly resistant to common treatment methods. The TME of this type of cancer is immune-suppressive and no activity of immune cells against the tumor can be seen in it. Currently, several immunotherapy approaches, including the use of oncolytic viruses, constitute the most prominent advances in cancer treatment. Oncolytic viruses lead to the direct lysis of tumor cells and by attracting and calling different immune cells to the TME, they cause an anti-tumor immune response. In this way, the penetration and absorption of immune cells to the tumor, cytotoxicity activity, death of tumor cells, and overcoming the immunosuppressive TME increases and tumor growth decreases. Based on studies, our proposed research plan with the production of an oncolytic virus and its effect on cancer cells is a promising approach that can lead to effective and safe treatment for cancer. In this study, we want to investigate the effect of a strain of oncolytic vaccinia virus on NSCLC cell lines in cell culture conditions and mouse model. For this purpose, we will measure the cytotoxicity of the virus and further investigate the effect of the virus on the processes of angiogenesis, apoptosis, and immunity. Also, after creating a xenograft model of non-small cell lung cancer in mice, we will investigate the effect of this virus in an animal model. Currently, we do not have a printable result of this article available and the project is ongoing. According to the measures taken, the preliminary results will be reported by the time of the congress. If the results of this research are consistent with the expected assumptions, it can lead to the development of the production and use of oncolytic viruses in preclinical and clinical trials. It can also be used as a new product in the treatment of various types of cancers and lead to the improvement of a patient's condition.

کلیدواژه ها:

oncolytic viruses ، vaccinia virus ، natural killer cells ، non-small cell lung cancer ، combination therapy